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Abstract 
Clinical trials in psychiatry inherit methods for design and statistical analysis from evidence-based 
medicine.  However, trials in other clinical disciplines benefit from a more specific relationship 
between instruments that measure disease state (e.g. biomarkers, clinical signs), the underlying 
pathology and diagnosis such that primary outcomes can be readily defined.  Trials in psychiatry 
use diagnosis (i.e. a categorical label for a syndrome) as a proxy for the underlying disorder, and 
outcomes are defined, for example, as a percentage change in a univariate total score on some 
clinical instrument.  We label this approach to defining outcomes weak aggregation of disease state.  
Univariate measures are necessary, because statistical methodology is both tractable and well-
developed for scalar outcomes, but we show that weak aggregate approaches do not capture disease 
state sufficiently, potentially leading to loss of information about response to intervention.  We 
demonstrate how multivariate disease state can be captured using geometric concepts of spaces 
defined over routine clinical instruments, and show how clinically meaningful disease states (e.g. 
representing different profiles of symptoms, recovery or remission) can be defined as prototypes 
(geometric locations) in these spaces.  Then, we show how to derive univariate (scalar) measures 
which capture patient’s relationships to these prototypes and argue these represent strong 
aggregates of disease state that may be a better basis for outcome measures.  We demonstrate our 
proposal using a large publically available dataset.   We conclude by discussing the impact of strong 
aggregates for analyses in traditional and novel trial designs. 
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1. Introduction 
 
A clinician from any discipline selects a treatment for a patient based on evidence from clinical 
trials.  The clinician applies the evidence based on the assumption that the patient has a given 
disease and that available treatments produce an outcome – response, remission or failure to 
respond - for that disease.  We will argue that currently, much of the clinical trial evidence in 
psychiatry relies on the assumption that diagnosis is an adequate proxy for a disease or disorder and 
this leads us to use an inappropriate model of outcome (Joyce et al. 2017).  This results in evidence 
that informs us only of the average response for a group of patients presumed to be homogenous 
with respect to their categorical diagnosis.  This may also explain the limited changes in prescribing 
practices after the publication of large trials (Berkowitz et al. 2012). 
 
Figure 1-1 describes a model of the relationship between trial outcomes and the underlying 
disorder; a concrete example being chronic systemic inflammatory disorders such as rheumatoid 
arthritis, where a disease process (DP: autoimmune-mediated inflammation) is reflected in a disease 
state (S: pain symptoms, inflammatory changes in joints, biochemical changes) that can be 
quantified by instruments (Y: pain and activity function scales; serological erythrocyte 
sedimentation rate, rheumatoid factor and anti-cyclic citrullinated peptide; radiological evidence of 
joint changes) and for which outcomes can be defined as changes in those instruments (Z: 
differences in pain and function scales, changes in serological markers and reduction in joint 
injury).  When a patient is treated, disease states (S) change, and if the instruments (Y) are sensitive 
to these changes, they can be subjected to statistical methods that establish treatment efficacy 
(response, or failure to respond) by e.g. defining thresholds on Z, and identifying which patient-
specific factors, X, mediate response. 
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In the idealised model shown in Figure 1-1, for a given disorder or disease process (DP) there will 
be a disease state (S) that corresponds with that disorder – but not necessarily in a one-one 
relationship.  The discovery of disease states and instruments that have predictive power to identify 
diagnoses is the domain of biomarker and psychometric research – see for example, (Marquand et 
al. 2016) for discussion of statistical methodology.  Here, we require that one or more instruments 
(Y) quantify variables of the disease state (S) at a given time and we take this collection of variables 
to be a vector identifying a location in a multidimensional space -- discussed below, and see also 
(Joyce et al. 2017) for a more detailed discussion.  It is, however, common practice in clinical trials 
to aggregate the variables in an instrument, Y, to obtain e.g. a total ‘score’ for measuring the 
severity of the patient’s disease state at any given time (i.e. pre- and post-intervention).  Finally, an 
outcome (Z) must then capture changes measured by instruments (Y) that are clinically meaningful.    
We recognise that the terms ‘disorder’, ‘disease’ and so forth can be contentious in mental health, 
but they are herein adopted for convention throughout this paper.  Further, as the analogy above 
suggests, we adopt a position consistent with biological realism (Kendler 2016) regarding the nature 
of psychiatric disorders. 
 
FIGURE 1 HERE 
 
Psychiatry does not benefit from as clear a correspondence between disease state (S) and disease 
process (DP) nor are there instruments (Y) analogous to erythrocyte sedimentation rate, radiological 
evidence or joint changes from the example of rheumatoid disease.  Consequently, psychiatry is 
faced with the model shown in Figure 1-2, where a diagnostic category (Dx) such as schizophrenia 
or bipolar affective disorder replaces disease process (DP). 
In psychiatry, the instruments (Y) that measure disease state are multivariate scales that capture the 
severity of signs and symptoms – for example, in psychotic disorders, the positive and negative  
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symptoms scale (PANSS) or the brief psychiatric rating scale (BPRS) (Kay et al. 1987; Overall & 
Gorham 1962)⁠ .    Psychiatric diagnoses represent constellations of signs and symptoms, but it is 
possible for these to overlap between diagnoses: for example psychotic features such as auditory 
verbal hallucinations are common to both schizophrenia, bipolar and major depressive disorder 
(Toh et al. 2015) and borderline personality disorder (Barnow et al. 2010; Schroeder et al. 2013; 
Glaser et al. 2010; Nishizono-Maher et al. 1993).  In bipolar disorder and schizophrenia, there are 
similarities in non-verbal communication (Annen et al. 2012)⁠ , affective symptoms (Keshavan et 
al. 2011)⁠  and cognitive deficits (Jabben et al. 2009; Green 2006)⁠ .    
 
There is also consensus, for example, that the diagnosis of schizophrenia is not a single disease 
process, but rather a categorical label for a syndrome with different aetiologies (Jablensky et al. 
2006; Ripke et al. 2014; Reininghaus et al. 2016; Walker et al. 2002; Demjaha et al. 2009; Demjaha 
et al. 2012)⁠  and shared genetic risk factors  (Lichtenstein et al. 2009; Craddock et al. 2009; Purcell 
et al. 2009)⁠ .  There is progress in trying to parse diagnostic categories along phenotypes, 
endophenotypes, biomarkers and underlying cellular and molecular aetiologies, for example 
(Schumann et al. 2014; Morris & Cuthbert 2012; Insel et al. 2010; Cuthbert & Insel 2013).  
 
Currently, clinical trials in psychiatry have to contend with a lack of clear relationship between 
disease state and process.  Patients are therefore recruited into trials on the basis of their diagnostic 
category (Dx) and treatment efficacy is established based on usually dichotomous outcomes (Z), 
defined as threshold changes in aggregates of instruments (Y).  For example, in mood disorders, 
remission of symptoms can be defined as the summed (total) Hamilton depression scale score of ≤ 7 
for at least 2 months (Frank et al. 1991), and similarly for schizophrenia, a 50% reduction in 
baseline PANSS or BPRS score (Leucht et al. 2009; Jakubovski et al. 2015).  In the language of 
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statistics, disease state and process (S and DP) are latent (or hidden, unmeasured) variables that are 
largely ignored.   
 
We will show that the model exemplified in Figure 1-2 results in patients being assigned the same 
outcome (Z) if we define aggregates on instruments (Y) without attending to differences in disease 
states (S).  For example, using the PANSS instrument, patients with high positive and low negative 
symptom severity risk being equated with patients who have low positive but high negative 
symptom severity.   Given the uncertainty in relationships between disease states and processes, 
ignoring how disease states differ between patients means we are effectively failing to identify 
groups of patients that may benefit from an intervention. Just as importantly, we may also be 
subjecting patients to treatments and side-effects that are not effective for their specific 
manifestation of disorder.   
 
Our proposal is that instead of assuming the model of Figure 1-2, adopting the model shown in 
Figure 1-1 allows the derivation of outcomes (Z) by directly attending to the concept of differing 
disease states as they are measured and represented by instruments (Y).  For example, at a given 
time, the PANSS instrument measures 30 individual symptoms – a measure of disease state – which 
can change over time, for example, in response to intervention.  We note that a single instrument 
may not be sufficient to capture disease state with enough fidelity to have analytical utility, for 
example, we may augment PANSS with some measure of affective symptoms or instruments 
measuring social and occupational functioning.  This has the potential to expose treatments that are 
effective for some patients (e.g. those with a certain profile of positive, negative and general 
symptoms) and avoids measuring efficacy as the ‘average’ response for the homogenous diagnostic 
category.  
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2. Weak Aggregate Outcomes 
 
To illustrate the inherent problems with current definitions of outcomes, consider the PANSS scale 
which measures 30 individual variables that if used to measure outcome are analytically intractable 
because clinical trial statistical methodology requires a univariate (one-dimensional or scalar) 
measure of change e.g. in response to treatment with respect to multiple predictors (i.e. patient 
specific factors, X, in Figure 1).  Tractability is obtained by ‘collapsing’ these 30 variables into a 
single aggregate by summation and then the outcome measure, Z, summarises clinically meaningful 
change (e.g. response or remission) as a threshold change in this sum.  We refer to this approach as 
weak aggregation.  For example, in mood disorders, remission of symptoms can be defined as the 
summed (total) Hamilton depression scale score of ≤ 7 for at least 2 months (Frank et al. 1991)⁠ .  
In schizophrenia, there are proposals for ways of aggregating variables in a more structured way 
(Andreasen et al. 2005)⁠  and these represent thresholds on selected combinations of variables in 
scales that are believed to be clinically meaningful.  However, clinical trials require a single primary 
outcome across the whole participant group, and secondary outcomes are used to measure subtle 
variation of response in sub-groups of the study population.  Using a number of secondary 
outcomes carries the cost of making analysis vulnerable to criticisms of false positives, or Type I 
error.  The most common approach to statistical analysis of this scalar outcome Z, is to use some 
variant of generalised linear modelling (GLM) against a set of predictors X (McCullagh & Nelder 
1989)⁠ . 
 
One consequence of the relationships described above, and in Figure 1, is that defining a primary 
outcome (Z) by thresholds on a weak aggregates of multiple variables (Y) ‘collapses’ information 
about patients’ disease state (S) into a single univariate, scalar value that may obscure important 
discriminating information that (optimistically) speaks to the disease process being treated by an 
intervention (as in the example given above of patients with opposing patterns of positive and 
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negative symptoms).  This is especially problematic for psychiatry, where the correspondence of 
disease states to processes stands in a many-to-many relationship and we have traditionally used 
diagnostic category (Dx) as a proxy for both.   
 
As a more detailed illustrative example, consider disease state measured by the three domains in the 
PANSS instrument: the total positive (P) and negative (N) symptoms scores range from 7 (no 
symptoms) to 49 (severe) and the general symptoms domain (G) ranges from 16 to 122.  To derive 
an outcome Z, we consider the weak aggregate that is the sum of the total positive and negative 
symptoms, Z = P + N.  It is obvious that there are many combinations of P and N (with each 
combination representing a discrete disease state) that could yield the same outcome value for Z. 
For example, a patient with P = 23 and N = 44 has Z = 67 whereas another patient with P = 38 and 
N = 29 has the same aggregate outcome Z = 67, despite these measurements representing quite 
different disease states;  the first patient having high negative (but low positive) symptom severity 
and the second patient having the opposite pattern.  Ignoring these differences – as the weak 
aggregate sum Z does – results in an outcome measure that cannot differentiate between disease 
states that may be clinically distinct and meaningful.  Using this example, there are 32 combinations 
of values for P and N that yield the sum 67 and therefore, 32 disease states which would be assigned 
the same outcome for the weak aggregate Z = P + N.  This problem becomes exponentially larger 
over three variables: defining the aggregate outcome measure over the positive, negative and 
general scales (Z = P + N + G) results in 741 discrete combinations of values of P, N and G that 
yield a total score of Z = 67.  Although some combinations assigned Z = 67 will be clinically 
meaningful - for example, patients with (P,N,G) = (18, 25, 24) and (18, 26, 23) are suitably alike  – 
in general, many will not.  It is clear that weak aggregation blindly collapses variables from 
instruments such as PANSS to a single scalar variable, ignoring clear differences in disease state. 
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3. Strong Aggregate Outcomes 
 
There is an additional problem with weak aggregation in psychiatry illustrated in Figure 1-2, when 
disease process and disease state are left un-modelled.  In standard analyses using GLMs, by 
definition, it is only the mean change in the aggregate outcome (Z) that is modelled as a function of 
the predictors (X).  All patients in the GLM analysis will be assumed to have effectively the same 
disorder that responds according to a unimodal, average response over the whole trial population:  
we know that response to an intervention is rarely uniform across patients with psychiatric 
disorders.  A relevant analogy in fibromyalgia is given by (Moore et al. 2013; Moore et al. 2010)⁠  
where response to treatment with pregabalin demonstrates a bimodal response; some patients have 
clinically significant reduction in pain but others show little or no response at all.   
 
Our proposal for strong aggregates is as follows: firstly, to retain the strengths and tractability 
inherent in current statistical methodology (e.g. GLMs) we must find univariate measures – but 
avoid simply ‘collapsing’ measurements of disease state into a single scalar which may not expose 
or reflect clinically meaningful differences (e.g. to avoid the problem exposed in the example above 
for positive and negative symptoms).  This requires a way of representing difference in disease 
state, as measured by instruments Y, so that the outcome Z will reflect clinically relevant differences 
in the inevitable variation in response between patients i.e. different ‘modes’ of response.  An 
additional (but less essential) requirement would be that the outcome can also be used to index 
patients who share similar disease states.  This might, for example, be suitable for use in N-of-1 trial 
designs (Schork 2015)⁠  to collect naturalistic evidence for treatments in the absence of complete 
understanding of disease process.    
 
4. Clinical Example 
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To illustrate our proposal, consider Figure 2 (equivalent colour versions can be found in 
Supplementary Information), that shows 1459 individual patient’s disease states as measured by the 
PANSS domain scores (positive, negative and general symptoms) from the baseline assessment of 
the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial (Stroup et al. 2003)⁠ .  
We use three variables purely to ease visualisation and exposition of the key concepts, 
acknowledging that we have summed the items in the PANSS to obtain three domains, but the 
principles will generalise and do not require summed domains.  Indeed, in practice, it would be 
prudent to use factor-analytic decompositions of these domains, see for example, (Wallwork et al. 
2012; Lindenmayer et al. 1995), but to keep our explanation simple and easy to visualise, we 
restrict ourselves to the 3 original groupings of signs and symptoms in PANSS.  In our example, the 
PANSS domains form a three-dimensional space, where each patient is represented by a point 
located on orthogonal (perpendicular) axes, representing low-to-high severity on positive (P), 
negative (N) and general (G) domains.  Visualising this space is difficult, so following standard 
practice in multivariate analysis, we present three ‘views’ obtained by plotting each combination of 
P, N and G in two-dimensional planes: P x N, G x P and N x G shown in Figure 2-1, 2-2 and 2-3 
respectively.   
 
FIGURE 2 HERE 
 
We then define 4 prototypes proposed to represent hypothesised disease states with clinically 
meaningful or interesting locations in this space: for example, prototype A represents disease states 
that are low severity across positive, negative and general symptoms (i.e. a relatively well patient).  
Prototype B represents the opposite extreme – a patient that is globally unwell with high symptom 
severity across positive, negative and general symptoms.   Prototype C represents a patient who has 
relatively high positive but low negative and relatively low general symptom severity.  Prototype D 
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represents a disease state where a patient has relatively low positive but high negative and general 
symptom severity.  Note that in defining prototypes, we are specifying structure with respect to the 
actual study population that can be exploited to define an outcome that preserves (rather than 
collapses) information that has clinical relevance, as required by our definition of strong aggregates.  
Patients with disease states near prototype A (relatively well) are clearly very different to those near 
B (globally unwell), and similarly for C and D where these patients are far from ‘well’ but whose 
disease states reflect different patterns of disease state.   
 
4.1 Measures Derived from Weak Aggregates 
 
Figure 2-4 shows the resulting univariate (i.e. one-dimensional) scale of the summed weak 
aggregate (where Z = P + N + G), with the location of each patient and the four prototypes along 
this scalar measure by their respective scores Z.   Of note, relatively well (A) and globally unwell 
(B) prototypes are well demarcated (i.e. distant) at each end of the univariate scale, but C and D less 
so.  This stands in contrast to the relative positions in the original space where C, D and B are well 
separated along the positive and negative symptoms dimension (Figure 2-1) as well as C and D 
being distinguished along both general and positive (Figure 2-2) negative and general dimensions 
(Figure 2-3).  The critical point is that a weak aggregate can only discriminate between well and 
unwell patients.   This is emphasised in the original three-dimensional space where each point (a 
single patient) in Figures 2-1, 2-2 and 2-3 are shaded light-to-dark according to their weak 
(summed) aggregate score Z (e.g. the greyscale of the points and scale bar shown in Figure 2-4).  
Notice how the gradient from light-to-dark (reflecting low to high Z) is broadly uniform in direction 
(bottom left to top right) over each of the three views, enabling distinction between A and B, but 
less so for C, and poorly for B and D.  This demonstrates graphically how weak aggregates collapse 
and obscure meaningful distinctions between potential different disease states unless they remain 
well separated on the univariate scale of Z (Figure 2-4).   
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4.2 Measures Derived from Strong Aggregates 
 
We now consider how the structure displayed in the prototypes can be captured in a way that 
enables a univariate outcome measure to be derived, but preserving distinctions between them in a 
meaningful way i.e. strong aggregation.   The method we used was singular value decomposition 
(SVD) which is similar to principle components analysis (Strang 2004), embedding a high-
dimensional space into a lower dimensional representation and in this case, exposes properties of 
interest (e.g. the separation of clinically relevant prototypes).  We note that SVD is one of many 
possibilities for this embedding transformation; the key requirements of any chosen method are 
dimensionality reduction with distance preservation (isometry) and other approaches include, for 
example, multidimensional scaling (Krzanowski 2000), isomap embedding (Tenenbaum et al. 
2000), locally linear embedding (Roweis & Saul 2000) and self-organising maps (Kohonen 1995)⁠ . 
Essentially, rather than ‘blindly’ summing, we use a method of combining or mapping each variable 
from Y (equivalently, the axes in Figure 2) such that clinically relevant regions of that space 
(prototypes in Figure 2) are mapped onto sufficiently different values in the univariate aggregate Z.  
After applying SVD to the same patients and prototypes in Figure 2, we are able to find a new, 
univariate strong aggregate that preserves the proposed clinically relevant difference in disease 
states exemplified by the prototypes (details are given in Supplementary Information).   
 
FIGURE 3 HERE 
 
Figure 3-4 shows the shape of the new strong univariate aggregate Z (using a soft rather than hard 
threshold scheme) with the new values of the prototypes illustrated.  This aggregate crucially 
separates the clinically relevant prototypes C and D (compared to the weak aggregate shown in 
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Figure 2).  In Figures 3-1, 3-2 and 3-3 (colour versions are reproduced in Supplementary 
Information), the patients in Figure 2 are assigned new values according to the strong aggregate Z 
(light grey = low Z, dark grey = high Z).  Note the difference in how the gradient of greyscales 
compares with Figure 2, emphasising the score of patients varying to their proximity along a line 
dividing C and D.   
 
5. Discussion and Conclusions 
 
In this paper, we have discussed how clinical trials in psychiatry have to cope with uncertain 
relationships between the treatment, disease state and process, and how this has potentially hindered 
clinical trial research.  Further, relationships among patients can be anchored to prototypes of 
clinical interest, in disease states as measured by clinical instruments. This may provide more useful 
information when defining outcomes by essentially exploiting geometric structure.  Our example 
used the PANSS as an exemplar instrument chosen for it’s general clinical familiarity, but the 
principles extend to any other instrument for other disorder areas (e.g. affective disorders and the 
Hamilton Depression Scale).    
 
We suggest increased use of strong aggregates because they capture important structure between 
regions of the measured disease state that weak aggregates ignore by blindly summing (or 
averaging) and that we have shown cause patients with different disease states to be mapped onto 
the same aggregate value.  We used one specific method (SVD) to define a strong aggregate, but 
any similar method that captures clinically relevant structure over regions of the space of disease 
states and then assigns a single univariate (scalar) variable that preserves the distance between these 
regions would be suitable.  Importantly, we defined prototypes only with respect to the actual 
patient population – remaining agnostic to the actual unknown disease process or classical 
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diagnostic category, but specifying tentative clinically relevant disease states.  The resulting strong 
aggregate is univariate and therefore compatible with current statistical methodology.  We now 
consider specific implications for trial methodology, design and analysis. 
 
5.1 Prototype and Response Definition 
The crux of our proposal is that univariate strong aggregates expose differences between relevant 
prototypes.  In the example provided earlier, we chose four prototypes in the 3-dimensional space of 
positive, negative and general symptoms representing globally well (A), globally unwell (B), as 
well as dominantly positive (C) and negative symptoms (D).  As a further example of a priori 
prototypes, the remission criteria defined in (Andreasen et al. 2005) can be interpreted in our 
framework as follows;  one dimension measures reality distortion (R, the sum of items P1, G9 and 
P3), another captures disorganisation (D, sum of P2, G5) and another captures negative symptoms 
(N, the sum of N1, N4 and N6)⁠ .  This similarly forms a 3-dimensional space with axes R, D and N 
that can be visualised similarly to the examples presented earlier.  There are then two relevant 
prototypes capturing the two extremes of full (best) and no (worst) remission.  The participants and 
prototypes are then transformed into a space V (e.g. Supplementary Information, Figure S3; by 
singular-valued decomposition) which can then be visualised to find the single univariate 
dimension, V*, that best exposes the gradient between these two extreme prototypes.  Prior to the 
trial intervention, each participant is then assigned a value (the strong aggregate) defined as their 
location along this dimension V* (as in Figure 3-4 above) that defines the participant’s pre-
intervention remission state.  At the end of the trial, each participant’s post-treatment values of R, D, 
and N are transformed into V, and their positions along the dimension V* are ‘read off’ resulting in 
the participant’s strong aggregate measure of remission state after intervention.  Alternatively, a 
‘hard’ threshold over V* can be defined – for example, if seeking to use the strong aggregate in a 
binary logistic/probit GLM analysis.  We note that in principle, disease states and prototypes need 
not be restricted to measures in 3-dimensional space and is used here only for ease of exposition.  
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The key is that one identifies the single dimension (in the transformation, by e.g. SVD) that exposes 
the differences between prototypes. 
 
5.2 Power and Recruitment  
In calculating a priori the sample size required for an adequately powered trial, the distribution of 
the data, the expected effect size (means) or response rate, and measures of variance are required.   
Therefore, just as for weak aggregates used as outcomes, if data is available from previous studies 
or pilot data, then the distribution, means/response rates and variance assumptions should be 
justified by applying the proposed strong aggregate definition on available pilot data.  Our proposal 
for strong aggregates is motivated by the idea that we may be failing to capture meaningful 
differences using weak aggregates; for this reason, there is potential to increase the power of a 
given study design. 
 
Recruitment to a prospective trial need not differ when using strong aggregates – however, they 
offer a potential advantage because participants are assigned a continuous univariate score based on 
their relationship to prototypes (see Figure 3).  The prototypes can define not only proposed or 
desired endpoints (e.g. defining two prototypes at extremes of positive symptoms) but also, 
‘landmarks’ of interest (for example, as we did for prototypes A, B, C and D in the above 
examples).  Then, participants could be stratified to treatment by their score in relation to prototypes 
– for example, those closer to prototype A may be assigned one treatment, those closer to prototype 
B another.   Further, we note a further application in N-of-1 trials, where diagnostic uncertainty is 
likely to be even more problematic and uncontrolled; in such instances, using SVD, it is straight-
forward to index patients by their similarity to each other and their similarity to prototypes.  In 
practice, a new patient attending a clinic with a certain disease state (e.g. measured by PANSS) can 
be easily compared to patients and prototypes using an SVD model (see Supplementary 
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Information), assigned a predicted outcome and stratified to treatment if, historically, there were 
treatments that worked for patients similarly proximal to certain prototypes.   
 
5.3 Trial Data Re-analysis 
One compelling reason to use strong aggregates is that it mitigates against multiple secondary 
analyses by i) requiring prototypes to be a priori defined to capture the proposed disease states (e.g. 
globally well, or dominant negative symptoms) relevant to the intervention and ii) providing a 
univariate measure over these disease states that reflects a given participant’s symptoms (or 
response to a treatment).  We suggest this prevents the scenario where, after failing to find a desired 
result using a weak aggregate primary outcome, secondary analyses are then required on ‘subsets’ 
of participants.  Necessarily, defining prototypes forces us to consider the clinically meaningful 
states – rather than looking for a global change in e.g. ‘total’ PANSS scores – and provides a way to 
define a single measure that captures participants’ disease state relative to these.  There is 
significant potential for many re-analyses of existing data using this paradigm.  To illustrate, we 
recently conducted a systematic review of trials for treating the cognitive symptoms of 
schizophrenia registered on ClinicalTrials.org in the period 2004-2015 (Joyce et al. 2017). We 
identified a total of 114 studies, but when we specifically examined definitions of primary outcome 
and available results, only 18 were eligible for inclusion.  We explored the definition of primary 
outcomes on instruments (e.g. PANSS), finding only 4 of the 18 studies considered specific 
combinations of variables or domain scores (a necessary first step to define prototypes for strong 
aggregates) instead of using weak aggregates.  Unsurprisingly, secondary outcomes were often used 
to understand the multi-dimensional (rather than univariate) measurement of disease state. 
In summary, the implications of our proposal are two-fold; first, given our arguments for the 
importance of disease state, we should reorient clinical trials toward recruiting for specific 
symptoms rather than diagnoses.  Second, clinical trial analyses should explore and then exploit the 
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heterogeneity of disease states (measured by familiar clinical instruments) and seek strong 
aggregates that focus outcomes on specific, relevant definitions of treatment response or failure 
rather than assuming homogeneity, weak aggregation and settling for the average response for a 
diagnostic category.   
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Figure Captions :  
 
Figure 1 : 1 (left) illustrates the typical model of a clinical trial in medicine. 2 (right) illustrates the 
typical model as applied to psychiatry, where there is a lack of a clear link between disease 
state (S) and disease process (DP) and consequently, they are usually replaced by a 
diagnostic category (Dx).  Arrows indicate dependence relations between variables – for 
example, disease state (S) depends on the disease process (DP). 
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Figure S1 – Colour Version of Weak Aggregate (Main Text – Figure 2) 
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Figure S2 – Colour Version of Strong Aggregate (Main Text – Figure 3) 
 
 
Application of Singular Valued Decomposition (SVD) to Derive Strong Aggregate 
Suppose that, as in the main text, the distinction between disease states in the neighbourhood 
of prototypes C and D are clinically relevant.  Using the positive, negative and general 
symptom domain scores for each patient, a 3-dimensional space is formed, shown in Figure 2 
and 3 of the main text, and above, in colour form.   
 
We first define the M x N matrix, Y, where rows, M, are variables measuring clinical state 
e.g. PANSS domains (positive, negative and general respectively) and the columns are values 
of each variable for the 1459 patients.  We then append to Y the prototypes A, B, C and D 
resulting in N = 1463. 
 An SVD (Strang, 2004) decomposes Y into three matrices: 
Y = UΣVT 
Where U and V are square matrices (the so-called left and right singular vectors) whose 
columns are the orthogonal eigenvectors of the matrix YY𝑇 and Y𝑇Y respectively.  Elements 
(i,j) of Y𝑇𝐘 represent a measure of similarity between patients i and j based on co-occurrence 
of their PANSS domains scores (positive, negative and general). Σ is the diagonal matrix of 
singular values of 𝐘.   
 
We can now examine the pattern of similarity between patients and prototypes by using only 
the columns of V representing the 3 largest singular values - resulting in a matrix of size 1463 
x 3, which can be visualised as shown in Figure S3.     
 
Figure S3 
 
By inspection, we find that the prototypes of clinical relevance that we wish to emphasise 
(see main text), C and D, are most separated along the axis V3 (corresponding to the 3rd 
singular value).  We label this the best or optimal dimension V*.  To form a univariate score, 
we simply retrieve the position of each of the 1459 points (for each patient) on V*.  To define 
our strong aggregate (in the traditional sense of a univariate outcome), we can then use either 
a hard or soft threshold.  In the former, we chose a fixed point along V*, and all patients 
higher/lower are assigned a binary outcome (which could represent for example, response or 
non-response).  Alternatively, we used a ‘soft-threshold’, assigning each patients’ strong 
aggregate value according to a smooth function over their values along V* (Figure 3 in the 
main text, shown in colour above as Figure S2).   
Using SVD For Matching / Retrieving Patients 
In the Discussions and Conclusions of the main text, we suggested that beyond defining 
strong aggregates, the formulation of SVD has utility for ‘matching’ patients.  In this 
application - as it is in information retrieval and latent semantic indexing (Manning, 
Raghavan and Shutze, 2008) – given an SVD of some set of patients represented by Y defined 
as before (e.g. rows correspond to variables measuring clinical state via an instrument  such 
as PANSS items or domains, with columns again representing individual patients), a new 
patient becomes a ‘query’ for which we seek similar patients and measure the proximity of 
the new patient to prototypes.    
 
Assume an SVD has been constructed in exactly the same way as before, but now, we retain 
some number k of the singular values (i.e. rather than 3, we might opt for larger k).  This 
results in the reduced-rank representation of Y as follows:  
Yk=UkΣkVk
T 
Yk is now a lower-dimensional approximation of the original Y that, by virtue of retaining 
only a subset of the largest k singular-values, reduces redundancy and noise, emphasising the 
dominant similarities between patients’ clinical states.  Any new patient 𝑦′ represented by 
their state in the original space Y can be queried for similarity to other patients and prototypes 
by first computing their projection into the lower dimensional space Yk : 
𝑦𝑘
′ =  𝚺𝑘
−1U𝑘
𝑇𝑦′ 
Then, comparison to other patients (and prototypes) proceeds by measuring the cosine 
similarity between 𝑦𝑘
′  and columns of Vk
T – see (Manning, Raghavan and Shutze, 2008) for 
further details and demonstration. 
